Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:27:15 2024-04-22 pm EDT			5-day change	1st Jan Change
1.695 ^USD	-2.02%		-0.29%	+51.81%

Apr. 16	Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI	MT
Apr. 16	Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	MT

Arch Biopartners : 2021 Q2 FS

August 30, 2021 at 11:52 pm EDT

ARCH BIOPARTNERS INC.

Condensed Interim Consolidated

Financial Statements

Nine Months Ended June 30, 2021 and 2020

(Unaudited - See Notice Of No Auditor Review)

ARCH BIOPARTNERS INC.

Index to Condensed Interim Consolidated Financial Statements

Nine Months Ended June 30, 2021 and 2020

(Unaudited - See Notice of No Auditor Review)

	Page
NOTICE OF NO AUDITOR REVIEW	1
INTERIM FINANCIAL STATEMENTS
Condensed Interim Consolidated Statement of Financial Position	2
Condensed Interim Consolidated Statement of Comprehensive Income (Loss)	3
Condensed Interim Consolidated Statement of Changes in Equity	4
Condensed Interim Consolidated Statement of Cash Flow	5
Notes to Condensed Interim Consolidated Financial Statements	6 - 24

NOTICE OF NO AUDITOR REVIEW

To the shareholders of Arch Biopartners Inc.

The accompanying unaudited condensed interim consolidated financial statements have been prepared by and are the responsibility of the management of the Company.

In accordance with National Instrument 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudited condensed interim consolidated financial statements for the period ended June 30, 2021.

"Richard Muruve" CEO and Director

ARCH BIOPARTNERS INC.

Condensed Interim Consolidated Statement of Financial Position

June 30, 2021 and September 30, 2020

(Unaudited - See Notice of No Auditor Review)

		June 30,		September 30,
		2021		2020
ASSETS
CURRENT	$	62,649
Cash	$	653,685
Amounts receivable from the Department of Innovation, Science, and		1,997,078
Economic Development (Note 13)			-
Australian research and development credit (Note 4)		366,098		-
Prepaid expenses		6,653		26,617
Harmonized sales tax receivable		268,329		60,999
	$	2,700,807	$	741,301
LIABILITIES
CURRENT	$	1,493,727
Accounts payable and accrued liabilities	$	949,227
Short term debt (Note 14)		2,251,836		-
Interest payable on convertible debt (Note 7)		385,699		269,767
		4,131,262		1,218,994
DEFERRED CONVERTIBLE DEBT (Note 7)		3,100,000		3,100,000
DUE TO SHAREHOLDER (Note 8)		290,821		290,411
		7,522,083		4,609,405
SHAREHOLDERS' EQUITY		14,485,052
Share capital (Note 9)			13,712,552
Contributed surplus (Note 9)		4,663,114		4,565,998
Deficit		(23,969,442)		(22,146,654)
		(4,821,276)		(3,868,104)
	$	2,700,807	$	741,301

ON BEHALF OF THE BOARD
	"Richard Muruve"	Director
	"Andrew Bishop"	Director

See notes to financial statements

ARCH BIOPARTNERS INC.

Condensed Interim Consolidated Statement of Comprehensive Income (Loss)

Nine Months Ended June 30, 2021 and 2020

(Unaudited - See Notice of No Auditor Review)

		3 months ended	3 months ended	9 months ended	9 months ended
			June 30,		June 30,		June 30,		June 30,
			2021		2020		2021		2020
REVENUE	$	1,997,078	$	29,572	$	2,018,163
Industry grants	$	85,223
EXPENSES			3,050				7,639
Communication				1,998			5,700
Insurance			7,030		3,608		22,838		7,446
Interest and bank charges			441		57		769		710
Interest on long-term debt (Note 8)			42,989		47,402		128,642		129,669
Interest on short-term debt			51,836		-		51,836		-
Marketing			10,557		27,429		19,160		47,214
Office			4,766		4,818		12,702		14,999
Patent			75,767		70,411		137,170		194,897
Professional fees			72,559		76,078		232,126		158,715
Regulatory and exchange fees			4,273		-		47,478		-
Research (Note 4)			771,616		297,938		2,909,477		678,851
Share based payments (Note 9)			12,488		1,619,655		97,116		1,642,566
Transfer agent fee			12,433		24,208		36,097		75,214
Travel			331		128		1,064		6,480
Wages and employee benefits			49,698		49,609		145,124		146,234
			1,119,834		2,223,339		3,849,238		3,108,695
INCOME (LOSS) FROM
OPERATIONS			877,244		(2,193,767)		(1,831,075)		(3,023,472)
FOREIGN EXCHANGE GAIN
(LOSS)			4,725		3,508		8,287		4,827
NET COMPREHENSIVE INCOME
(LOSS)	$	881,969	$	(2,190,259)	$	(1,822,788)	$	(3,018,645)
BASIC EARNINGS (LOSS) PER
SHARE	$	0.014	$	(0.037)	$	(0.030)	$	(0.051)
DILUTED EARNINGS (LOSS) PER
SHARE	$	0.013	$	(0.037)	$	(0.030)	$	(0.051)
WEIGHTED AVERAGE NUMBER
OF SHARES OUTSTANDING			61,462,302		59,950,780		61,202,118		59,603,181

See notes to financial statements

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

Original document
Permalink

Disclaimer

Arch Biopartners Inc. published this content on 31 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 31 August 2021 03:51:07 UTC.

Latest news about Arch Biopartners Inc.

Arch Biopartners Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-AKI	Apr. 16	MT
Arch Biopartners Brief: Says St. Michael's Hospital Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Apr. 16	MT
Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Apr. 16	CI
Arch Biopartners Says University Health Network Joining Phase II Trial of LSALT Peptide	Apr. 03	MT
Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	Apr. 03	CI
Arch Biopartners Adds Three Clinical Sites in Turkey For Phase II Trial for LSALT Peptide	Apr. 02	MT
Arch Biopartners Adds Three New Clinical Sites into the Phase Ii Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Apr. 02	CI
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation	Mar. 18	MT
Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2	Mar. 18	CI
Arch Biopartners Says University of Calgary Joins Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated AKI	Mar. 15	MT
University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Mar. 15	CI
Arch Biopartners Announces Dosing Of Patient In Phase II Trial For LSALT Peptide	Mar. 07	MT
Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury	Mar. 07	CI
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for Lsalt Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Feb. 29	CI
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase Ii Cardiac Surgery Associated-Acute Kidney Injury Trial for Lsalt Peptide	Feb. 29	CI
Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial	Feb. 29	CI
Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 28	CI
Arch Biopartners on Pre-IND Meeting With FDA to Repurpose Cilastatin as New Treatment to Prevent Acute Kidney Injury	Feb. 27	MT
Arch Biopartners Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Jan. 28	CI
Arch Biopartners Inc.(TSXV:ARCH) added to S&P/TSX Venture Composite Index	Jan. 22	CI
Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial For LSALT Peptide	Jan. 10	MT
Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Jan. 10	CI
Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide	Jan. 03	MT
Arch Biopartners Inc. Receives Approval from the Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury	Jan. 03	CI
Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide	Dec. 21	CI

Chart Arch Biopartners Inc.

Duration

Period

More charts

Company Profile

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. It focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. It has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

Sector

Biotechnology & Medical Research

Calendar

2024-05-27 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.327 CAD

Average target price

3.5 CAD

Spread / Average Target

+50.43%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARCH BIOPARTNERS INC.	+51.81%	107M
IQVIA HOLDINGS INC.	-0.02%	42.11B
LONZA GROUP AG	+45.66%	40.08B
MODERNA, INC.	+5.04%	40B
CELLTRION, INC.	-11.32%	26.87B
ICON PUBLIC LIMITED COMPANY	+5.25%	24.58B
ALNYLAM PHARMACEUTICALS, INC.	-23.83%	18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.94B
MEDPACE HOLDINGS, INC.	+22.75%	11.66B
UNITED THERAPEUTICS CORPORATION	+6.44%	11.01B

Other Biotechnology & Medical Research